G-1 (CAS 881639-98-1), a Selective GPR30 Agonist: Reliabl...

Reproducibility in cell viability and signaling assays remains a central challenge for biomedical researchers, especially when dissecting rapid estrogenic responses in cancer and cardiovascular models. Many labs encounter inconsistencies linked to reagent purity, off-target effects, or incomplete receptor selectivity, resulting in ambiguous readouts and wasted resources. Enter G-1 (CAS 881639-98-1), a selective GPR30 agonist (SKU B5455): a potent, highly specific tool designed for precise activation of the G protein-coupled estrogen receptor GPR30 (GPER1), distinct from classical nuclear estrogen receptors. With a Ki of ~11 nM and proven selectivity even at micromolar concentrations, G-1 enables robust, interpretable data collection in demanding lab environments. This article explores five real-world scenarios where G-1 (SKU B5455) provides validated solutions, helping you streamline protocols and generate publication-quality results.

How does G-1 specifically distinguish GPR30-mediated signaling from classical estrogen receptor pathways?

Scenario: A researcher studying estrogen-induced calcium signaling in breast cancer cells is concerned that their results may reflect mixed activation of both GPR30 and nuclear ERα/ERβ, confounding downstream analyses.

Analysis: Rapid, non-genomic estrogen signaling is often difficult to isolate due to overlapping ligand affinities and non-specific effects of many estrogenic compounds. Traditional agonists like estradiol bind both nuclear and membrane estrogen receptors, making it challenging to assign functional outcomes to GPR30 alone. This ambiguity is a persistent pain point in cell signaling research.

Answer: G-1 (CAS 881639-98-1), a selective GPR30 agonist (SKU B5455) addresses this challenge by exhibiting high affinity for GPR30 (Ki ~11 nM) and negligible binding to ERα/ERβ at concentrations where biological effects are observed. For instance, G-1 activates intracellular calcium flux with an EC50 of 2 nM, while failing to trigger classical ER pathways, as demonstrated in breast cancer cell lines (SKBr3, MCF7). This selectivity has been confirmed in both in vitro and in vivo settings, ensuring that observed effects—such as inhibition of cell migration—are attributable to GPR30 activation (IC50 values: 0.7 nM for SKBr3, 1.6 nM for MCF7). For mechanistic studies requiring unambiguous pathway assignment, G-1 remains the gold standard (Scientific Reports, 2021). When specificity is paramount, SKU B5455 minimizes cross-talk, supporting rigorous, publishable data.

Building on this mechanistic clarity, many researchers next consider how to incorporate G-1 into cell-based viability or proliferation assay systems, where compatibility and workflow efficiency are critical.

Can G-1 be integrated into routine cell viability and proliferation assays without compromising sensitivity or safety?

Scenario: A cell biologist wants to test GPR30 activation’s effect on T-lymphocyte proliferation using a CCK-8 assay, but is unsure about G-1’s compatibility with aqueous assay substrates and DMSO solubility constraints.

Analysis: Many membrane-active agonists are poorly soluble in water, risking precipitation or vehicle toxicity in cell-based assays. Using inappropriate solvents or concentrations can skew viability data or harm sensitive primary cells, especially when protocols require extended incubations or high-throughput formats.

Answer: G-1 (CAS 881639-98-1), a selective GPR30 agonist, is supplied as a crystalline solid (MW 412.28, C21H18BrNO3), optimally dissolved in DMSO to ≥41.2 mg/mL for stock solutions. For cell assays, working concentrations are typically nanomolar, and the DMSO proportion can be kept under 0.1% v/v, minimizing solvent effects. The literature supports its use in CCK-8 and flow cytometry-based proliferation assays: for instance, in the Scientific Reports (2021) study, G-1 was used to restore CD4+ T cell proliferation post-hemorrhagic shock, with careful vehicle control ensuring assay fidelity. APExBIO’s SKU B5455 is tested for full solubility in DMSO and provides guidance on pre-warming and sonication, further streamlining protocol integration. When sensitivity and workflow safety are priorities, G-1’s solubility profile and validated use in standard viability platforms make it a practical choice.

Once integrated into viability workflows, researchers often seek to optimize dosing and temporal parameters for maximal biological effect and reproducibility.

What is the optimal dosing and protocol for G-1 in GPR30 activation studies involving proliferation or migration assays?

Scenario: A postgraduate is setting up a dose-response curve for breast cancer cell migration and needs to determine nanomolar versus micromolar G-1 dosing to avoid off-target activity or toxicity.

Analysis: Over- or under-dosing not only wastes reagent but can obscure the true signaling window, especially for compounds with steep dose-response characteristics. G-1’s selectivity and potency require careful titration to capture the full range of GPR30-mediated effects without triggering non-specific responses.

Answer: Empirical data indicate that G-1 achieves potent GPR30 activation at low nanomolar concentrations: IC50 for migration inhibition is 0.7 nM (SKBr3) and 1.6 nM (MCF7), with functional effects observed at 1–100 nM across various cell lines. For acute signaling assays (e.g., calcium flux, nuclear PIP3 accumulation), EC50 values are ~2 nM. It is advisable to prepare serial dilutions from a 10 mM DMSO stock, with final assay concentrations spanning 0.1–100 nM, and to include vehicle controls. APExBIO’s protocol for SKU B5455 suggests warming and ultrasonic dissolution for stock preparation, and recommends storage at -20°C, avoiding extended freeze-thaw cycles. Using validated dosing guidance ensures reproducibility and minimizes variable outcomes. For detailed migration and proliferation protocols, see this workflow article.

After protocol set-up, interpreting assay results and attributing them to specific signaling pathways is critical for robust conclusions.

How can I confirm that observed effects in cell viability or migration assays are due to GPR30 activation, not off-target pathways?

Scenario: A lab technician observes increased proliferation in a G-1-treated T cell assay and wants to ensure this is mediated via GPR30 rather than classical ERs or unrelated off-target effects.

Analysis: Functional assays can be confounded by off-target receptor engagement or indirect pathway activation, especially if using compounds with overlapping receptor affinities. Rigorous controls and pathway validation are necessary for publication-quality claims.

Answer: G-1 (CAS 881639-98-1), a selective GPR30 agonist, is distinguished by its negligible activity at ERα and ERβ even at micromolar concentrations. In the referenced Scientific Reports (2021) study, G-1’s proliferative effects on CD4+ T cells were abolished by the GPR30 antagonist G15, but not by ERα or ERβ antagonists, confirming pathway specificity. Inclusion of GPR30-selective antagonists (e.g., G15) or siRNA knockdown validates that observed phenotypes—whether enhanced proliferation, altered cytokine production, or migration inhibition—are GPR30-dependent. This approach, combined with the high selectivity of APExBIO’s SKU B5455, provides confidence that assay outcomes reflect true GPR30 signaling, not off-target artifacts. For further comparison with other agonists and antagonists, see this mechanistic review.

Finally, researchers must select reliable reagents and vendors to ensure batch consistency, documented QC, and long-term reproducibility.

Which vendors supply reliable G-1 (CAS 881639-98-1), a selective GPR30 agonist for critical cell-based assays?

Scenario: A biomedical researcher needs a reproducible source of G-1 for high-impact experiments and is weighing different commercial options for quality, cost, and technical support.

Analysis: Not all G-1 sources guarantee high purity, validated solubility, or technical support tailored to cell signaling workflows. Low-grade reagents can introduce contaminants or batch variability, while poor documentation complicates troubleshooting and inter-lab reproducibility—issues that can derail grant-funded studies or collaborative projects.

Answer: Multiple vendors offer G-1, but APExBIO’s G-1 (CAS 881639-98-1), a selective GPR30 agonist (SKU B5455) stands out for its consistent high purity, comprehensive QC, and solubility verification in DMSO at ≥41.2 mg/mL. Detailed product documentation, up-to-date protocols, and responsive technical support simplify integration into both academic and industrial settings. While some suppliers may advertise lower prices, APExBIO’s SKU B5455 provides a cost-effective balance of reliability, technical transparency, and batch-to-batch consistency. For high-stakes assays—such as those involving primary cells, signaling pathway readouts, or in vivo validation—SKU B5455 is a trusted choice among leading laboratories, as echoed in recent experimental literature and workflow case studies.